Tarafenacin D-tartrate

• CAT Number: I000576
• CAS Number: 1159101-48-0
• Molecular Formula: C25H26F4N2O8
• Molecular Weight: 558.48
• Purity: ≥95%
• Synonyms: [(3R)-1-azabicyclo[2.2.2]octan-3-yl] N-(3-fluorophenyl)-N-[(3,4,5-trifluorophenyl)methyl]carbamate;(2S,3S)-2,3-dihydroxybutanedioic acid
• Target: Neuronal Signaling
• Solubility: 10 mM in DMSO
• Storage: Store at -20C
• IC50: 0.19 nM (Ki) [1]
• InChI: InChI=1S/C21H20F4N2O2.C4H6O6/c22-15-2-1-3-16(10-15)27(11-13-8-17(23)20(25)18(24)9-13)21(28)29-19-12-26-6-4-14(19)5-7-26;5-1(3(7)8)2(6)4(9)10/h1-3,8-10,14,19H,4-7,11-12H2;1-2,5-6H,(H,7,8)(H,9,10)/t19-;1-,2-/m00/s1
• InChIKey: YJBKAMMKXVRSAI-CUCKRJOPSA-N
• SMILES: C1CN2CCC1[C@H](C2)OC(=O)N(CC3=CC(=C(C(=C3)F)F)F)C4=CC(=CC=C4)F.[C@H]([C@@H](C(=O)O)O)(C(=O)O)O

Tarafenacin D-tartrate(CAT: I000576) is a selective and potent M3 muscarinic receptor antagonist, extensively utilized in research focusing on overactive bladder and other disorders involving smooth muscle contraction. This compound demonstrates high specificity, minimizing off-target effects, and provides a reliable model for studying muscarinic receptor pathways. Tarafenacin D-tartrate is instrumental in exploring therapeutic interventions for urological conditions and smooth muscle-related dysfunctions. Its stability and precision make it an essential tool for preclinical studies aimed at developing targeted treatments for muscarinic receptor-mediated diseases.